Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline versus duloxetine versus antispasmodic treatment for irritable bowel syndrome
IRCT20210420051023N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sertraline, duloxetine and mebeverine in irritable bowel syndrome (IBS) (3 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Change in anxiety, Change in bloating or abdominal distension and 1 more. Started Sep 2021; status: completed.
02
Drugs
sertralineduloxetinemebeverine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20210420051023N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210420051023N1.